Chih-Cheng Lai1, Meng-Tse Gabriel Lee2, Shih-Hao Lee2, Wan-Ting Hsu2, Shy-Shin Chang3, Shyr-Chyr Chen2, Chien-Chang Lee4. 1. Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan. 2. Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan. 3. Department of Family Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan. 4. Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan Department of Emergency Medicine, National Taiwan University Hospital, Yunlin Branch, Douliou, Taiwan.
Abstract
BACKGROUND: Epidemiological data suggest that statins improve the clinical outcome of respiratory infections. We sought to examine whether statin therapy decreases the risk of active TB. METHODS: We conducted a nested case-control study on data obtained from a national health insurance claims database between 1999 and 2011. The use of statins was classified as current, recent, past or chronic use. Three conditional logistic regression models were used to estimate the incidence rate ratios (RRs). The first assessed the effect of statin use without further adjustment; the second adjusted (individually) for 75 potential confounders; and the third adjusted for the Disease Risk Score (DRS). RESULTS: A total of 8098 new TB cases and 809 800 control patients were examined. All four types of statin users showed a decreased risk of active TB. Chronic use (>90 days in a calendar year) of statins was associated with the lowest unadjusted risk of TB (RR 0.74; 95% CI 0.63 to 0.87). The protective effect of active TB remained after adjusting for individual confounders (RR 0.66; 95% CI 0.56 to 0.78) and after DRS adjustment (RR 0.62; 95% CI 0.53 to 0.72). The effect estimates obtained for chronic and current use of statins were very similar. We also found that the active TB protection increased with increasing length of statin prescription. CONCLUSIONS: We found that statin therapy was associated with a decreased risk of active TB, and the length of statin therapy affected the TB protection. Given the observational nature of this study, the protective effect against active TB must be confirmed in future randomised trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: Epidemiological data suggest that statins improve the clinical outcome of respiratory infections. We sought to examine whether statin therapy decreases the risk of active TB. METHODS: We conducted a nested case-control study on data obtained from a national health insurance claims database between 1999 and 2011. The use of statins was classified as current, recent, past or chronic use. Three conditional logistic regression models were used to estimate the incidence rate ratios (RRs). The first assessed the effect of statin use without further adjustment; the second adjusted (individually) for 75 potential confounders; and the third adjusted for the Disease Risk Score (DRS). RESULTS: A total of 8098 new TB cases and 809 800 control patients were examined. All four types of statin users showed a decreased risk of active TB. Chronic use (>90 days in a calendar year) of statins was associated with the lowest unadjusted risk of TB (RR 0.74; 95% CI 0.63 to 0.87). The protective effect of active TB remained after adjusting for individual confounders (RR 0.66; 95% CI 0.56 to 0.78) and after DRS adjustment (RR 0.62; 95% CI 0.53 to 0.72). The effect estimates obtained for chronic and current use of statins were very similar. We also found that the active TB protection increased with increasing length of statin prescription. CONCLUSIONS: We found that statin therapy was associated with a decreased risk of active TB, and the length of statin therapy affected the TB protection. Given the observational nature of this study, the protective effect against active TB must be confirmed in future randomised trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Blanca I Restrepo; Léanie Kleynhans; Alejandra B Salinas; Bassent Abdelbary; Happy Tshivhula; Genesis P Aguillón-Durán; Carine Kunsevi-Kilola; Gloria Salinas; Kim Stanley; Stephanus T Malherbe; Elizna Maasdorp; Moncerrato Garcia-Viveros; Ilze Louw; Esperanza M Garcia-Oropesa; Juan Carlos Lopez-Alvarenga; John B Prins; Gerhard Walzl; Larry S Schlesinger; Katharina Ronacher Journal: Tuberculosis (Edinb) Date: 2018-08-18 Impact factor: 3.131
Authors: Min-Chul Kim; Sung-Cheol Yun; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim Journal: Am J Trop Med Hyg Date: 2019-08 Impact factor: 2.345
Authors: Noton K Dutta; Natalie Bruiners; Matthew D Zimmerman; Shumin Tan; Véronique Dartois; Maria L Gennaro; Petros C Karakousis Journal: J Infect Dis Date: 2020-03-16 Impact factor: 5.226
Authors: Eduardo P Amaral; Caian L Vinhaes; Deivide Oliveira-de-Souza; Betania Nogueira; Kevan M Akrami; Bruno B Andrade Journal: Antioxid Redox Signal Date: 2020-06-19 Impact factor: 8.401
Authors: Cari Stek; Brian Allwood; Naomi F Walker; Robert J Wilkinson; Lutgarde Lynen; Graeme Meintjes Journal: Front Microbiol Date: 2018-10-30 Impact factor: 5.640